Puma Biotechnology (PBYI) Q3 2026 earnings review
Puma Biotechnology raises its profit plan, but drug discounts grow
Puma Biotechnology, the maker of breast cancer pill NERLYNX, beat its profit plan on tight overhead while pricing and generic pressures hit revenue. Total revenue grew 1% to $55 million, missing the company's outlook after generic competition in China triggered a $2 million royalty reduction. Chief executive Alan Auerbach also noted that steeper Medicaid and 340B hospital discounts weighed on US sales, though lower administrative costs and zero debt interest still lifted net income to $6 million.
| NERLYNX net product revenue | $54.1M +4.2% from a year ago (plan: $54–$56M) |
|---|---|
| Royalty revenue | $1.0M −62% after a $2.1M China generic charge |
| GAAP net income | $6.0M −32% from a year ago (plan: $2–$3.5M) |
| Full-year net income outlook | Raised $2.5M $20–$22M; total revenue trimmed $2M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because lower overhead costs offset weakening commercial pricing, leaving the company's future dependent on upcoming clinical trial readouts. Puma raised its full-year net income plan and started its second lung cancer study for experimental drug alisertib on schedule. The bad news: two long-standing revenue risks materialised at once, as China generics permanently lowered the royalty rate and government discounts forced management to worsen its full-year discount outlook.
The question now is whether rising US prescription volume can outrun the shift toward heavily discounted 340B hospital and Medicaid channels while Puma waits for alisertib trial data. Either underlying patient starts are strong enough to keep revenue growing, or discount mix and China generics will shrink the cash engine just as late-stage trial costs arrive. Updated breast cancer data in December 2026 and bottle volume details from the quarterly filing will tell.
🐂 Bull Case
Tight Overhead Lifted the Full-Year Profit Plan
Puma wants to fund its experimental cancer trials out of current profits while keeping its balance sheet free of debt. Three months ago, the company forecast just $2 million to $3.5 million in third-quarter net income, which pointed to a sharp jump in operating costs.
Instead, the drugmaker earned $6.0 million in the third quarter and raised its full-year profit outlook to $20 million to $22 million. Selling, general and administrative expenses — day-to-day overhead and sales force costs — fell 1.2 percentage points of revenue from a year ago to 29.6%. Paying off its debt in May also eliminated $1.5 million of quarterly interest expense.
This cost discipline matters because it lets Puma pay for its expanding clinical trials without borrowing money. Net income still fell from $8.8 million a year ago because research and manufacturing costs rose, so profit growth depends on trial results rather than further overhead cuts.
What to watch: fourth-quarter net income against the $10 million to $12 million outlook. Meeting that range will confirm that Puma can absorb its higher trial spending while generating over $20 million in annual profit.
Alisertib Added a Second Lung Trial on Schedule
Because NERLYNX is an older breast cancer drug facing generic and pricing pressure, Puma's future rests on alisertib, an oral cancer pill it licensed in 2022. Chief executive Alan Auerbach had promised to start a second lung cancer study in the third quarter and present updated breast cancer data before year-end.
Puma started the ALISCA-Lung2 Phase II trial in September, testing alisertib alongside the chemotherapy drug paclitaxel in small cell lung cancer. Auerbach also confirmed the December 2026 breast cancer data presentation at the San Antonio symposium and added a new milestone for the first half of 2027: "initiation of discussions with global regulatory agencies regarding the Phase III trial design for alisertib in combination with endocrine treatment".
Research and development spending rose 4.0 percentage points of revenue from a year ago to 33.2%, "reflecting increased alisertib study activity". Keeping the trials on schedule brings the company closer to a late-stage study, though Phase II efficacy data still has to prove the drug works.
What to watch: the ALISCA-Breast1 Phase II data at the San Antonio Breast Cancer Symposium in December 2026. Strong tumour responses in biomarker-selected patients are needed to justify the planned 2027 regulatory talks.
🐻 Bear Case
Government Discounts Are Eating Into US Sales Growth
Puma has argued that rising US patient demand is turning NERLYNX around. For the third quarter, the company had forecast that its gross-to-net adjustment — the percentage of list price lost to rebates and discounts — would ease to between 26% and 27%.
Instead, Auerbach said US sales were hit by "higher than expected gross to net due to an increase in Medicaid and 340B sales", referring to government-mandated discount programmes for low-income patients and eligible hospitals. Net product revenue of $54.1 million barely cleared the bottom of the $54 million to $56 million outlook, ending a run of five beats in six quarters.
- Q3 net product revenue: $54.1 million, up 4.2% from a year ago
- Full-year discount outlook: raised to 27.5%–28%, from 26.5%–27.5%
- Q4 discount outlook: 28%–29%, the highest since the first quarter's seasonal reset
This cuts against the turnaround story because growth is coming from discounted hospital and government channels, so Puma keeps less money per bottle sold. Even with delayed foreign orders shifting into the fourth quarter, management only narrowed its full-year product sales outlook around the same $207 million middle of the range.
What to watch: the exact third-quarter discount rate and bottle volume on the earnings call and in the quarterly filing. If bottle demand grew high single digits while net revenue rose only 4.2%, discount mix is absorbing roughly half of the volume gains.
China Generic Competition Triggered a Royalty Cut
Outside the United States, Puma licenses NERLYNX to regional partners and collects royalties on their sales, primarily in China. Management had warned that its royalty rate in China would step down once generic copies of the drug took a specific share of the market.
That threshold was crossed this quarter. Puma booked a $2.1 million reduction to third-quarter royalty revenue after receiving third-party market data "confirming that the market share of generic versions of NERLYNX in China reached a specified threshold during the period". Reported royalty revenue fell to $1.0 million, missing the $2 million to $3 million outlook; by our math, royalties would have been $3.1 million without the accounting adjustment.
Puma also cut its full-year royalty plan from $19 million to $22 million down to $18 million to $19 million. Because the contractual rate is now permanently lower, China royalties will contribute less cash to fund research in 2027 and beyond.
What to watch: fourth-quarter royalty revenue against the $11 million to $12 million outlook, which relies on a large year-end China shipment. The size of the drop from last fourth quarter's $15.6 million will show how much the lower royalty rate hurts peak quarterly collections.
Partner Shipments Squeezed Margins and Shifted Into Q4
Sales of NERLYNX supply to international partners are lumpy and carry much lower profit margins than US sales. In the third quarter, Auerbach noted "a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter".
Even with that delay, cost of sales — the cost of making the drug and royalties Puma owes its own licensor — jumped from $12.2 million to $15.2 million, or 5.2 percentage points of revenue, "due primarily to higher product sales to an international partner". Gross margin fell from 77.6% to 72.4% by our math, showing that partner shipments both swing revenue between quarters and dilute margins when they land.
What to watch: the split between US and international product revenue in the quarterly filing. That breakdown will show how much of the third quarter's 4.2% product revenue growth came from low-margin foreign supply rather than US patients.
Risks this quarter didn't answer
Four standing concerns from prior quarters could not be tested from the earnings release alone, because Puma discloses commercial volume details on its conference call and in its quarterly filing.
- US demand bottles and new patient starts: the release states US demand grew from a year ago, but gives no bottle count or new-patient start rate to show whether patients are starting treatment or just refilling.
- Exact Q3 discount rate: management said discounts exceeded the 26%–27% plan, but the call or filing is needed for the exact figure.
- US import tariffs on patented drugs: a 100% Section 232 duty took effect September 29, 2026 while Puma manufactures in Europe; the release did not mention tariffs or raw-material inventory.
- Alisertib dosing and Phase III funding pace: no new clinical data was due in the third quarter; the December 2026 breast cancer readout is the next test.
💲 Other KPIs
Cash generated from operations rose 50.5% from a year ago to $14.6 million, rebounding from $1.6 million in the second quarter. That lifted cash and marketable securities to $108.5 million, up $11.0 million since December 2025 despite paying off all $22.5 million of debt in the first half.
Diluted shares rose 4.3% from a year ago, faster than the 3.6% growth a year earlier, as employee stock grants vested and Puma did not buy back shares. Higher share count trimmed per-share profit growth by about 4 percentage points compared with net income.
Profit per diluted share excluding stock-based compensation fell 28.6% from $0.21 a year ago, reversing the second quarter's 26.7% gain. The cancer drugmaker's non-cash stock compensation rose slightly to $2.0 million, or 5.8% of overhead and research costs.
🔮 Guidance
Raised. The middle of the range moved up $2.5 million to $21 million, though full-year profit is still set to fall 32.5% from 2025 by our math due to higher clinical trial spending. It is the third raise this year: +$6.0M, +$1.0M, +$2.5M. The Q4 outlook of $10–$12 million implies an 18% drop from last Q4.
Unchanged at the $207 million middle of the range for the full year, implying 1.4% growth over 2025 after two earlier raises (+$8M, +$3M, $0M). The new Q4 plan of $56–$58 million is up 5.4% from Q3 on delayed partner orders, but down 4.8% from a year ago against a high comparison that included partner shipments and distributor stocking.
Cut. The full-year middle of the range dropped by $2 million after generic competition in China triggered a lower royalty rate. The new Q4 outlook of $11–$12 million still relies on a large fourth-quarter China shipment, but sits 26.3% below last year's $15.6 million fourth-quarter royalty.
Cut at the top end, lowering the full-year middle of the range by $2 million to $225.5 million, or a 1.3% decline from 2025 by our math. The new Q4 outlook of $67–$70 million is down 9.3% from a year ago at the middle of the range because both product sales and China royalties face high year-ago comparisons.
Worsened. Management raised the full-year discount range by 0.75 percentage points at the middle of the range, which reduces net revenue. The new Q4 outlook of 28%–29% shows that higher Medicaid and 340B hospital discounts are expected to build further at year-end.
❓ Key Questions
What were Q3 US bottle sales and new patient starts?
The release says US demand grew from a year ago, but does not give bottle counts or new patient prescriptions. Investors need those figures from the call to see if new patients are starting NERLYNX or if growth only comes from refills.
How much did the China royalty rate step down?
Generic competitors in China crossed the market-share threshold in Q3, triggering a $2.1 million charge and a lower royalty outlook. Management has not disclosed the old or new royalty percentage, which sets the baseline for 2027 royalty cash flow.
How much of Q3 product sales went to international partners?
Cost of sales jumped $3.0 million on higher international partner shipments even as other foreign orders slipped into Q4. Disclosing the exact partner supply revenue will show how much US revenue actually grew after higher Medicaid and 340B discounts.
Will the new US drug import tariffs hit 2027 margins?
A 100% US tariff on imported patented drugs took effect on September 29, 2026, and Puma makes its drugs at European contractors. The release did not mention tariffs, leaving open whether Puma's earlier inventory build shields it from duty costs.